We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Paxton Green Group Practice
Inclisiran Requests
We are currently declining to take over requests to take over prescribing and administration of Inclisiran.
Following consideration as a practice, this is because of ongoing concerns regarding the safety and resources required for practices to administer Inclisiran:
- 3 to 4 year data from trials suggests that the drug is well tolerated. However, there is currently no data from long term large outcome trials. Long-term efficacy data is expected to be published in 2026
- Until then, long term evidence on effectiveness and safety is lacking.
- Inclisiran is a black triangle drug.
- This means it is a newer drug that requires extra vigilance for rare side effects.
- Therefore clinicians administering the medication should be able to undertake shared decision making with the patient, ensuring a detailed consent is taken and documenting currently unknown long term evidence and safety profile.
- GPs are not currently in the position to provide this information.
- General practices are not currently commissioned or resourced to provide the specialist administration/ training and monitoring that this medication requires.